This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Colchicine in acute gout

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Colchicine is used in patients with heart failure or other contra-indications to treatment with NSAIDs.

  • colchicine is a naturally occurring alkaloid derived from autumn crocus
    • for acute gout it should be given orally in doses of 0.5 mg 2-4 times daily (1). Previously, the British National Formulary (BNF) recommended the use of colchicine in higher doses, for example 1 mg immediately followed by 0.5 mg every 2-4 hours until pain abates or gastrointestinal side-effects occur. Gastrointestinal symptoms such as diarrhoea and vomiting occur very frequently with such highdose regimes. Low-dose colchicine, as advocated above, is as effective as high-dose regimes but has fewer gastrointestinal side-effects.

Adverse effects of colchicine

  • common side effects are diarrhoea and gastric irritation
  • rare side effects include renal failure, myopathy, cardiac arrhythmia, respiratory failure and peripheral neuropathy
  • chronic treatment may cause a blood dyscrasia.

The summary of product characteristics must be consulted before prescribing this drug.

Reference:

  1. Arthritis Research UK (2011). Hands On (9) - gout: presentation and management in primary care.
  2. Drug and Therapeutics Bulletin 2004 ;42(5):37-40.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.